European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics…
HOUSTON, July 10, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology…
Read More...
Read More...